How does bupropion interact with warfarin (Jantoven) and what monitoring is required when co‑prescribing them?

Bupropion and Warfarin (Jantoven) Interaction

Bupropion can be safely co-prescribed with warfarin (Jantoven), but requires close INR monitoring when starting, stopping, or changing the bupropion dose, as abrupt discontinuation may cause significant INR elevation and bleeding risk.

Mechanism and Clinical Evidence

Bupropion is not listed among the major CYP450 inhibitors or inducers that interact with warfarin in the FDA labeling 1 or in the 2022 comprehensive guideline on oral anticoagulant drug interactions 2. The guideline extensively details psychotropic interactions with warfarin, specifically highlighting SSRIs (fluoxetine, fluvoxamine), carbamazepine, phenytoin, quetiapine, valproic acid, and trazodone—but bupropion is notably absent from this list 2.

However, one case report documents a clinically significant interaction: a patient on stable bupropion developed deep vein thrombosis and was started on warfarin. When bupropion was abruptly discontinued, the INR increased more than two-fold above the therapeutic range (high bleeding risk). The INR normalized when bupropion was reintroduced, suggesting bupropion may induce warfarin metabolism 3.

Practical Management Algorithm

When Co-Prescribing:

1. Baseline INR before starting bupropion in warfarin-stabilized patients
2. Check INR at 3-5 days after bupropion initiation
3. Weekly INR monitoring for 2-3 weeks until stable
4. Resume standard monitoring (every 1-4 weeks) once therapeutic range maintained 1

When Discontinuing Bupropion:

• Critical: Check INR within 3-5 days of stopping bupropion
• Monitor twice weekly for 2 weeks as INR may rise significantly
• Be prepared to reduce warfarin dose if INR becomes supratherapeutic
• Watch for bleeding signs (bruising, hematuria, melena, epistaxis)

Dose Adjustments:

• No preemptive warfarin dose change is recommended when starting bupropion (unlike gemfibrozil which requires 20% reduction 2)
• Adjust warfarin based on INR response, not prophylactically
• If INR rises >4.0, consider holding 1-2 warfarin doses and recheck INR 1

Important Caveats

The interaction is bidirectional but unpredictable: Unlike well-characterized interactions (SSRIs double bleeding risk 2; carbamazepine requires 50% warfarin increase 2), the bupropion-warfarin interaction is based on limited evidence—essentially one case report 3. This makes the interaction potentially dangerous because it's unexpected.

Never abruptly stop bupropion in warfarin patients without INR monitoring, as the case report showed dramatic INR elevation when bupropion was discontinued 3.

The FDA labeling emphasizes that "more frequent INR monitoring should be performed when starting or stopping other drugs" 1, which applies to bupropion despite its absence from specific interaction lists.

Comparison to Other Antidepressants

If concerned about interactions, consider that:

• SSRIs (especially fluoxetine, fluvoxamine) more than double bleeding risk via CYP2C9/3A4 inhibition 2
• Sertraline and citalopram/escitalopram are safer SSRI alternatives 2
• Mirtazapine increases bleeding risk (OR 1.75) 4
• Bupropion has minimal documented interaction but requires vigilance based on the case report 3

Bottom line: Bupropion is not contraindicated with warfarin, but the single case report of significant INR elevation upon discontinuation warrants structured INR monitoring during any bupropion dose changes 3.